Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mandorfer, M; Steiner, S; Schwabl, P; Payer, BA; Aichelburg, MC; Lang, G; Grabmeier-Pfistershammer, K; Trauner, M; Peck-Radosavljevic, M; Reiberger, T.
Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
J Infect Dis. 2015; 211(5):729-735
Doi: 10.1093/infdis/jiu516
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Trauner Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The HIVCOBOC-RGT study (NCT01925183) was the first study to evaluate response-guided shortening of the duration of boceprevir (BOC)-based triple therapy in human immunodeficiency virus (HIV)/hepatitis C virus genotype 1-coinfected patients (HIV/HCV-GT1). After 4 weeks of pegylated interferon-α-2a/ribavirin (PEGIFN/RBV) lead-in, patients with target-not-detectable HCV-RNA at week 8 (rapid virologic response; LI4W-W8UTND) received 24 weeks of BOC/PEGIFN/RBV (total: 28 weeks [W28]). Patients with target-detectable HCV-RNA at week 8 received 44 weeks of BOC/PEGIFN/RBV (total: 48 weeks [W48]). Fourteen patients (67%) had LI4W-W8UTND and were eligible for the shortened W28 arm, while 7 (33%) patients were allocated to the W48 arm. No breakthrough or relapse occurred in the W28 arm, resulting in a sustained virologic response (SVR12TND) rate of 100% (12/12). In the W48 arm, the SVR12TND was 50% (3/6), with 3 patients meeting the futility rule at treatment week 12. The preliminary overall SVR12TND rate was 83% (15/18). Serious adverse events were observed in 5 (24%) patients, with 2 (10%) patients requiring surgical treatment of abscesses. The majority of HIV/HCV-GT1 were eligible for response-guided shortening of treatment duration to W28 and all of these patients had a SVR12TND. If second-generation direct-acting antivirals are not available, W28 of BOC-based triple therapy may be recommended. © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antiviral Agents - administration & dosage
- Antiviral Agents - adverse effects
- Drug Monitoring -
- Drug-Related Side Effects and Adverse Reactions - epidemiology
- Drug-Related Side Effects and Adverse Reactions - pathology
- Female -
- HIV Infections - complications
- Hepatitis C, Chronic - complications
- Hepatitis C, Chronic - drug therapy
- Humans -
- Interferon-alpha - administration & dosage
- Male -
- Middle Aged -
- Polyethylene Glycols - administration & dosage
- Proline - administration & dosage
- Proline - adverse effects
- Proline - analogs & derivatives
- RNA, Viral - blood
- Recombinant Proteins - administration & dosage
- Ribavirin - administration & dosage
- Treatment Outcome -
- Find related publications in this database (Keywords)
- antiviral agents
- boceprevir
- hepatitis C
- HIV
- response-guided therapy